Global CAR T Cell Therapy Market & Clinical Trials Insight 2022

  • ID: 4210270
  • Drug Pipelines
  • Region: Global
  • 240 Pages
  • Kuick Research
1 of 5
Currently, there Are 99 Car T Cell Based Therapies in Clinical Pipeline and Most of them Belong to Phase-I and Phase-I/II Clinical Trials

FEATURED COMPANIES

  • Autolus
  • Bluebird
  • Cellectis
  • Eureka Therapeutics
  • Immune Therapeutics
  • Kite Pharma
  • MORE

“Global CAR T Cell Therapy Market & Clinical Trials Insight 2022” report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials.

In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex.

The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients.

The first commercial application of CAR T Cell based therapy for the treatment of Mantle- Non-Hodgkin's lymphoma is expected to be available from 2020. The anti-CD19 CAR T cell therapy axicabtagene ciloleucel (KTE-C19) is developed by KITE Pharma in collaboration with National Cancer Institute. Currently this therapy is in preregistration phase.

In future, the advancement of CAR T Cell therapy will be largely driven by academia and will require the support for the expensive early phase clinical trials which promise to cover the way for a new form of targeted, exportable immunotherapy for cancer patient. The manufacturing of CD19 CAR T cell therapy CTL019 is in a way which will modernize the process of using the therapy globally. The anticipation of regulatory and manufacturing issues before they arise and proactively addressing the concerns helps to accelerate the process of bringing this promising therapeutic approach to more patients in future.

“Global CAR T Cell Therapy Market & Clinical Trials Insight 2022” report highlights:

  • CAR T Cell Therapies Delivery Pipeline & Mechanism of Action
  • Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
  • Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase
  • Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies
  • CAR T Cell Therapies in Highest Phase: Preregistration
  • Majority of CAR T Cell Therapies in Phase-I/II Trials: 16 Therapies
  • Global Market Scenario of CAR T Cell Therapy
  • Global CAR T Cell Therapy Market Future Prospects
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Autolus
  • Bluebird
  • Cellectis
  • Eureka Therapeutics
  • Immune Therapeutics
  • Kite Pharma
  • MORE

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology
1.1 Overview
1.2 History & Development of CAR-T Technology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
2.1 Structure of CAR T Cell
2.2 1nd Generation Chimeric Antigen Receptor
2.3 2nd & 3nd Generation CAR T Cell

3. Principle of Chimeric Antigen Receptor Design
3.1 CAR Modified T Cells: Targeting
3.2 CAR Modified T Cell: Signaling

4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action
4.1 Process of CAR T Cell Therapy
4.2 Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy
5.1 Introduction
5.2 Targeting the Tumor Stroma with CAR T Cells
5.3 Targeting the Cytokine Networks
5.4 Combination Strategies for CAR T Cells
5.5 Targeting the Immune Checkpoints

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
6.1 Acute Lymphoblastic Leukemia
6.2 Multiple Myeloma
6.3 Brain Tumors
6.4 Lymphoma
6.5 Solid Tumors

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Preregistration

8. Global Market Scenario of CAR T Cell Therapy
8.1 Overview
8.2 Estimated Price Analysis of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy
9.1 Market Share of Cancer Immunotherapy by its Technology
9.2 CAR T Cell Therapy Market Value

10. Global CAR T Cell Therapy Market Dynamics
10.1 Favorable Parameters
10.2 Challenges

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive Landscape
12.1 Autolus
12.2 Bellicum
12.3 Bluebird
12.4 Celgene
12.5 Cellectis
12.6 Celyad
12.7 Eureka Therapeutics
12.8 Fortress Biotech
12.9 Immune Therapeutics
12.10 Juno Therapeutics
12.11 Kite Pharma
12.12 Novartis
12.13 Sorrento therapeutics
12.14 TILT Biotherapeutics
12.15 Ziopharm

List of Tables:
Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor
Table 12-1: Clinical Pipelines of Products

List of Figures:
Figure 1-1: Historical Development of CAR T Cell Therapy
Figure 2-1: Structure of Chimeric Antigen Receptor
Figure 2-2: First Generation Chimeric Antigen Receptor
Figure 2-3: Second Generation Chimeric Antigen Receptor
Figure 2-4: Third Generation Chimeric Antigen Receptor
Figure 3-1: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
Figure 3-2: Signalling Mechanism of Chimeric Antigen Receptor T Cell
Figure 4-1: Delivery Pipeline of CAR T Cell Therapy Process
Figure 4-2: CAR T Cell Therapy Mechanism of Action
Figure 5-1: Strategies to Improve CAR T Cell Therapy
Figure 6-1: CAR T Cell Therapy in Brain Tumors
Figure 6-2: Chimeric Antigen Receptor Therapy in Lymphoma
Figure 6-3: Target of Cancer Cell by Chimeric Antigen Receptor
Figure 7-1: Global – CAR T Cell Therapy Clinical Pipeline by Phase (Number), 2017-2022
Figure 7-2: Global – CAR T Cell Therapy Clinical Pipeline by Phase (%), 2017-2022
Figure 8-1: Adoptive T-Cell Therapy - Open Clinical Trials to Investigate the Efficacy & Safety (%), 2015
Figure 8-2: Estimated Cost of T Cell Therapy & CAR T Cell Therapy Per Patient (US$)
Figure 9-1: Cancer Immunotherapy - Market Share of by Its Technology - (%)
Figure 9-2: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022
Figure 9-3: Global - Predictive Market of CAR T Cell Therapeutics (US$ Million), 2016-2022
Figure 10-1: Favorable Market Parameters of CAR T Cell Therapy
Figure 10-2: Challenges to Market Growth of CAR T Cell Therapy
Figure 11-1: Future Potential Immuno-Oncology

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Autolus
  • Bellicum
  • Bluebird
  • Celgene
  • Cellectis
  • Celyad
  • Eureka Therapeutics
  • Fortress Biotech
  • Immune Therapeutics
  • Juno Therapeutics
  • Kite Pharma
  • Novartis
  • Sorrento therapeutics
  • TILT Biotherapeutics
  • Ziopharm
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll